ArticleCase reports in dermatological medicine2025
Synchronous Macular Amyloidosis and Brachioradialis Pruritus Successfully Treated With Gabapentin.
Article in Case reports in dermatological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brachioradial pruritus (BRP) and macular amyloidosis (MA) are distinct dermatological conditions that have rarely been reported together. BRP is a neuropathic pruritus affecting the lateral forearm, whereas MA presents as hyperpigmented patches caused by amyloid deposition in the dermis. We report the first case of synchronous MA and BRP in a 45-year-old woman who presented with severe pruritus in the brachioradialis distribution, concurrent with hyperpigmented patches characteristic of MA. Cervical spine imaging revealed moderate-to-severe multilevel degenerative changes. The patient was successfully treated with gabapentin 200 mg daily, with significant improvement in both conditions. This case highlights the first reported synchronous presentation of MA and BRP and suggests potential shared pathophysiological mechanisms. The favorable dual therapeutic response to gabapentin provides new insights into management strategies for concurrent presentations of these conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.